A distinct microglial subset at the tumor–stroma interface of glioma. Issue 7 (11th March 2021)

• Record Type: Journal Article
• Authors: Caponegro, Michael D.; Oh, Ki; Madeira, Miguel M.; Radin, Daniel; Sterge, Nicholas; Tayyab, Maryam; Moffitt, Richard A.; Tsirka, Stella E.
• Is Part Of: Glia. Volume 69:Issue 7(2021)
• Page Start: 1767
• Page End: 1781
• Publication Date: 2021-03-11
• Subjects: CCL2 -- GAM -- glioma -- leading edge -- microglia -- P2RY12; Neuroglia -- Periodicals; Neurology -- Periodicals; 611.0188
• DOI: 10.1002/glia.23991
• Languages: English
• ISSNs: 0894-1491

Abstract

Abstract: The characterization of the tumor microenvironment (TME) in high grade gliomas (HGG) has generated significant interest in an effort to understand how neoplastic lesions in the central nervous system (CNS) are supported and to devise novel therapeutic targets. The TME of the CNS contains unique and specialized cells, including the resident myeloid cells, microglia. Myeloid involvement in HGG, such as glioblastoma, is associated with poor outcomes. Glioma‐associated microglia and infiltrating monocytes/macrophages (GAM) accumulate within the neoplastic lesion where they facilitate tumor growth and drive immunosuppression. However, it has been difficult to differentiate whether microglia and macrophages have similar or distinct roles in pathology, and if the spatial organization of these cells informs outcomes. Here, we characterize the tumor–stroma border and identify peritumoral GAM (PGAM) as a unique subpopulation of GAM. Using data mining and analyses of samples derived from both murine and human sources we show that PGAM exhibit a pro‐inflammatory and chemotactic phenotype that is associated with peripheral monocyte recruitment, and decreased overall survival. PGAM act as a unique subset of GAM at the tumor–stroma interface. We define a novel gene signature to identify these cells and suggest that PGAM constitute a cellular target of the TME. Main Points: Microglia at the border of glioma exhibit a pro‐inflammatory phenotype. Microglia‐specific gene expression dynamically changes at the tumor–stroma interface. Microglia at the tumor–stroma interface correlate with clinical outcomes of glioblastoma.